Colorectal surgery

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Thursday, March 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Thursday, March 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Retrieved on: 
Monday, February 5, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Roth Capital Partners, Immunity, Colorectal surgery, Trial of the century, Form S-1, AKI, Prospectus, Revelation, Disease, Infection, Sale, Suite, Form, Security (finance)

The warrants have an exercise price of $4.53 per share, are exercisable upon issuance, and will expire five years following the date of issuance.

Key Points: 
  • The warrants have an exercise price of $4.53 per share, are exercisable upon issuance, and will expire five years following the date of issuance.
  • Roth Capital Partners acted as sole placement agent for the offering.
  • The gross proceeds to the Company from the offering are approximately $6.2 million, before deducting the placement agent’s fees and other offering expenses payable by Revelation.
  • 333-276232), as amended, that was declared effective by the U.S. Securities and Exchange Commission (“SEC”), on January 31, 2024.

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

Retrieved on: 
Thursday, February 1, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Roth Capital Partners, Immunity, Colorectal surgery, Trial of the century, Form S-1, AKI, Prospectus, Revelation, Disease, Infection, Sale, Suite, Form, Security (finance)

The warrants will have an exercise price of $4.53 per share, are exercisable upon issuance, and will expire five years following the date of issuance.

Key Points: 
  • The warrants will have an exercise price of $4.53 per share, are exercisable upon issuance, and will expire five years following the date of issuance.
  • The closing of the offering is expected to occur on or about February 5, 2024, subject to the satisfaction of customary closing conditions.
  • Roth Capital Partners is acting as sole placement agent for the offering.
  • The gross proceeds to the Company from the offering are expected to be approximately $6.2 million, before deducting the placement agent’s fees and other offering expenses payable by Revelation.

Northwell Opens $52M Cancer Center, Multispecialty Practice in Queens

Retrieved on: 
Tuesday, November 28, 2023
General Health, Hospitals, Health, Practice Management, Oncology, Queens Boulevard, Hindi, Oncology nursing, North Shore University Hospital, Gynaecology, Cancer Institute, LIJ, New Yorker, Head, Cardiology, Endocrinology, Genetic counseling, Surgical oncology, Hematology, Elective surgery, DEXA, Internal medicine, Urology, Breast cancer, Google Images, Patient, Multimedia, Gastrointestinal cancer, Colorectal surgery, Kimelman Cancer Institute, Neurology, Heart, Obstetrics, Rheumatology, MD Anderson Cancer Center, Rehabilitation, Bariatrics, Lung cancer screening, Gastroenterology, HIV, Neurosurgery, Cancer, QMA, MRI, Social work, Hospital, PET, General surgery, STARS, Estate (law), Nursing, Management, MD, Northwell Health

As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.

Key Points: 
  • As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.
  • Northwell treats about 19,000 New Yorkers with cancer each year, more than any other cancer provider in the state.
  • “We’re excited to open a new outpatient cancer center in the heart of Queens to deliver the best cancer care close to where people live,” said Richard Barakat, MD , physician-in-chief and executive director of the Northwell Health Cancer Institute.
  • “Northwell is uniquely positioned to care for patients in Queens – one of the most diverse places in the country.

Savage Medical Exits Stealth With Over $3 Million to Enable Minimally Invasive Colorectal Tumor Removal

Retrieved on: 
Tuesday, November 28, 2023
SAN, Colorectal cancer, Robotics, Colorectal surgery, Clinical trial, Patient, Division, Emerging technologies, Stoma, Neoplasm, Dentistry

Capital raised contributes to SavageMed's ongoing clinical trial of its groundbreaking ColoSeal™ System.

Key Points: 
  • Capital raised contributes to SavageMed's ongoing clinical trial of its groundbreaking ColoSeal™ System.
  • "ColoSeal allows a one-time, minimally invasive procedure after the tumor removal that potentially eliminates the need for the additional surgical procedures and avoids need for an ostomy."
  • "Every year, there are 1.9 million people diagnosed with colorectal cancer.
  • Our vision is to replace the multiple surgical procedures and complications that hundreds of thousands of colorectal patients endure each year with a minimally invasive solution."

KelaHealth Surgical Intelligence Platform Helps Surgeons Avoid Serious Complications

Retrieved on: 
Monday, November 6, 2023
Technology, Professional Services, Health, General Health, Health Technology, Research, Data Analytics, Software, Artificial Intelligence, Surgery, Science, Aurora, Duke University Hospital, Intelligence, Heel, Intuitive Surgical, AKI, Multimedia, Advocate, Chronic kidney disease, Artificial intelligence, SSI, Risk, Surgeon, Partnership, Hospital, EHR, CKD, AI, Colorectal surgery, Patient, Death, Duke, Birth control, Medical device, MD

The study used the commercially-available KelaHealth Surgical Intelligence Platform, powered by machine-learning software, to identify patients who were at high risk for AKI and 30-day readmission following colorectal surgery.

Key Points: 
  • The study used the commercially-available KelaHealth Surgical Intelligence Platform, powered by machine-learning software, to identify patients who were at high risk for AKI and 30-day readmission following colorectal surgery.
  • To guide surgical treatment, the KelaHealth platform was embedded within the traditional clinical workflow, which enabled surgical care teams to receive and interpret data in a prospective and anticipatory manner.
  • Bora Chang, MD, KelaHealth’s founder and CEO added: “During our clinical validation phase we partnered with leading academic institutions and industry partners to demonstrate the real-time clinical benefits of a KelaHealth Surgical Intelligence Platform implementation.
  • With clinical results across multiple surgical disciplines now in hand, it’s clear hospitals need ‘more Kela’ in their workflows to drive better surgical outcomes.

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

Retrieved on: 
Monday, October 9, 2023
SHIELD, Large intestine, Colorectal surgery, American College, Pharmaceutical industry

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.

Key Points: 
  • PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.
  • Impact of Locally Applied Doxycycline-Eluting Drug (D-PLEX) on Incisional Infection Rate in Elective Colorectal Surgery: A Phase 3, Prospective, Randomized, Double-Blind, Multicenter, and Multinational Clinical Trial

FluidAI Medical Announces $15M in Series A Funding for AI-Driven Postoperative Monitor at HLTH 2023

Retrieved on: 
Tuesday, October 10, 2023
Surgery, Health, Death, Bleeding, Government, AI, Sepsis, Mortality, Wound healing, Artificial intelligence, Patient, Trust, Patient safety, Fungal infection, SOSV, Surgeon, Medtech, Disability, Colorectal surgery, Infection, Hospital, Nursing

MedTech FluidAI Medical secures funding to empower healthcare providers with data-driven insights to transform postoperative care.

Key Points: 
  • MedTech FluidAI Medical secures funding to empower healthcare providers with data-driven insights to transform postoperative care.
  • Following any surgical intervention, there are inherent risks of adverse outcomes, irrespective of how minor or major the procedure may be.
  • At FluidAI, our goal is to continuously push the boundaries of what's possible in postoperative care, ensuring patients recover safely and quickly.
  • "With FluidAI, surgeons can ensure better clinical outcomes, shorter hospital stays for patients, and cost efficiencies across the healthcare ecosystem.

Lipogems® Announces 140 independent Peer Reviewed Publications with 5 years of follow up in orthopaedics

Retrieved on: 
Friday, September 22, 2023
Science, Colorectal surgery, General surgery, FDA, Publication, Arthroscopy, Physician, Patient, Evidence-based medicine, Dentistry

ATLANTA, Sept. 22, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.

Key Points: 
  • ATLANTA, Sept. 22, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.
  • "Lipogems has sought out to help patients that have tried conservative options and other therapies with limited relief.
  • "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."
  • "Many physicians have patients that have exhausted other therapies and they don't have many options to help them.